Voyager Therapeutics(VYGR) - 2025 Q1 - Quarterly Results

EXHIBIT 99.1 Voyager Reports First Quarter 2025 Financial and Operating Results - Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg - - Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ 2025 continue to support tau as next critical target in Alzheimer's disease - LEXINGTON, Mass., May 6, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a bio ...